drugset / Trial / NCT02027311

Etomidate vs. Midazolam for Sedation During ERCP

NCT02027311

Phase 4 Completed 63 enrolled Cheju Halla General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system. The investigators are now trying to investigate that etomidate with meperidine combination regimen is superior to the midazolam with meperidine more effective and less harm on sedation during the ERCP procedure.

Timeline

Start
2013-04
Primary completion
2013-08
Completion
2013-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etomidate Small molecule 0.1 mg/kg Intravenous
Subject Midazolam Small molecule 0.06 mg/kg Intravenous
Background Meperidine Unknown 25 mg Intravenous
Background Meperidine Unknown 50 mg Intravenous